Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer
The goal of this study was to characterize the relationship between tumor uptake of 64Cu-DOTA-trastuzumab as measured by PET/CT and standard, immunohistochemistry (IHC)-based, histopathologic classification of human epidermal growth factor receptor 2 (HER2) status in women with metastatic breast can...
Gespeichert in:
| Veröffentlicht in: | The Journal of nuclear medicine (1978) 2018-01, Vol.59 (1), p.38-43 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 43 |
|---|---|
| container_issue | 1 |
| container_start_page | 38 |
| container_title | The Journal of nuclear medicine (1978) |
| container_volume | 59 |
| creator | Mortimer, Joanne E Bading, James R Park, Jinha M Frankel, Paul H Carroll, Mary I Tran, Tri T Poku, Erasmus K Rockne, Russell C Raubitschek, Andrew A Shively, John E Colcher, David M |
| description | The goal of this study was to characterize the relationship between tumor uptake of 64Cu-DOTA-trastuzumab as measured by PET/CT and standard, immunohistochemistry (IHC)-based, histopathologic classification of human epidermal growth factor receptor 2 (HER2) status in women with metastatic breast cancer (MBC). Methods: Women with biopsy-confirmed MBC and not given trastuzumab for 2 mo or more underwent complete staging, including 18F-FDG PET/CT. Patients were classified as HER2-positive (HER2+) or -negative (HER2-) based on fluorescence in situ hybridization (FISH)-supplemented immunohistochemistry of biopsied tumor tissue. Eighteen patients underwent 64Cu-DOTA-trastuzumab injection, preceded in 16 cases by trastuzumab infusion (45 mg). PET/CT was performed 21-25 (day 1) and 47-49 (day 2) h after 64Cu-DOTA-trastuzumab injection. Radiolabel uptake in prominent lesions was measured as SUVmax Average intrapatient SUVmax (pt) was compared between HER2+ and HER2- patients. Results: Eleven women were HER2+ (8 immunohistochemistry 3+; 3 immunohistochemistry 2+/FISH amplified), whereas 7 were HER2- (3 immunohistochemistry 2+/FISH nonamplified; 4 immunohistochemistry 1+). Median pt for day 1 and day 2 was 6.6 and 6.8 g/mL for HER 2+ and 3.7 and 4.3 g/mL for HER2- patients (P < 0.005 either day). The distributions of pt overlapped between the 2 groups, and interpatient variability was greater for HER2+ than HER2- disease (P < 0.005 and 0.001, respectively, on days 1 and 2). Conclusion: By 1 d after injection, uptake of 64Cu-DOTA-trastuzumab in MBC is strongly associated with patient HER2 status and is indicative of binding to HER2. The variability within and among HER2+ patients, as well as the overlap between the HER2+ and HER2- groups, suggests a role for 64Cu-DOTA-trastuzumab PET/CT in optimizing treatments that include trastuzumab.The goal of this study was to characterize the relationship between tumor uptake of 64Cu-DOTA-trastuzumab as measured by PET/CT and standard, immunohistochemistry (IHC)-based, histopathologic classification of human epidermal growth factor receptor 2 (HER2) status in women with metastatic breast cancer (MBC). Methods: Women with biopsy-confirmed MBC and not given trastuzumab for 2 mo or more underwent complete staging, including 18F-FDG PET/CT. Patients were classified as HER2-positive (HER2+) or -negative (HER2-) based on fluorescence in situ hybridization (FISH)-supplemented immunohistochemistry of biopsied tumor tissue. Eighteen pati |
| doi_str_mv | 10.2967/jnumed.117.193888 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5750523</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1912609094</sourcerecordid><originalsourceid>FETCH-LOGICAL-p216t-fde271c49fc91a1655d3ec3175fe1e190817946193ca751397b107f7a6f0291e3</originalsourceid><addsrcrecordid>eNpVkEtPwzAQhC0EolD4Adx85JLitWM7viCV8JSKyiE9R67r0JS8iG0Q_Hos0QOcdrSz-jSzCF0AmVEl5NWuC63dzADkDBTLsuwAnQBnPOFCyMM_eoJOndsRQkQ8OkYTmgkmM0JP0LIIbT_i1eD1m8V9hUWah-R2WcyTYtTOh-_Q6jWuO_yifW077_Bn7bf42froxpXBN6ONEue6M3Y8Q0eVbpw9388pWt3fFfljslg-POXzRTJQED6pNpZKMKmqjAINgvMNs4aB5JUFC4pkIFUqYiujJQem5BqIrKQWFaEKLJui61_uENbxByYmG3VTDmPd6vGr7HVd_ne6elu-9h8ll5xwyiLgcg8Y-_dgnS_b2hnbNLqzfXAlKKCCKKJS9gNmc2tm</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1912609094</pqid></control><display><type>article</type><title>Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Mortimer, Joanne E ; Bading, James R ; Park, Jinha M ; Frankel, Paul H ; Carroll, Mary I ; Tran, Tri T ; Poku, Erasmus K ; Rockne, Russell C ; Raubitschek, Andrew A ; Shively, John E ; Colcher, David M</creator><creatorcontrib>Mortimer, Joanne E ; Bading, James R ; Park, Jinha M ; Frankel, Paul H ; Carroll, Mary I ; Tran, Tri T ; Poku, Erasmus K ; Rockne, Russell C ; Raubitschek, Andrew A ; Shively, John E ; Colcher, David M</creatorcontrib><description>The goal of this study was to characterize the relationship between tumor uptake of 64Cu-DOTA-trastuzumab as measured by PET/CT and standard, immunohistochemistry (IHC)-based, histopathologic classification of human epidermal growth factor receptor 2 (HER2) status in women with metastatic breast cancer (MBC). Methods: Women with biopsy-confirmed MBC and not given trastuzumab for 2 mo or more underwent complete staging, including 18F-FDG PET/CT. Patients were classified as HER2-positive (HER2+) or -negative (HER2-) based on fluorescence in situ hybridization (FISH)-supplemented immunohistochemistry of biopsied tumor tissue. Eighteen patients underwent 64Cu-DOTA-trastuzumab injection, preceded in 16 cases by trastuzumab infusion (45 mg). PET/CT was performed 21-25 (day 1) and 47-49 (day 2) h after 64Cu-DOTA-trastuzumab injection. Radiolabel uptake in prominent lesions was measured as SUVmax Average intrapatient SUVmax (pt) was compared between HER2+ and HER2- patients. Results: Eleven women were HER2+ (8 immunohistochemistry 3+; 3 immunohistochemistry 2+/FISH amplified), whereas 7 were HER2- (3 immunohistochemistry 2+/FISH nonamplified; 4 immunohistochemistry 1+). Median pt for day 1 and day 2 was 6.6 and 6.8 g/mL for HER 2+ and 3.7 and 4.3 g/mL for HER2- patients (P < 0.005 either day). The distributions of pt overlapped between the 2 groups, and interpatient variability was greater for HER2+ than HER2- disease (P < 0.005 and 0.001, respectively, on days 1 and 2). Conclusion: By 1 d after injection, uptake of 64Cu-DOTA-trastuzumab in MBC is strongly associated with patient HER2 status and is indicative of binding to HER2. The variability within and among HER2+ patients, as well as the overlap between the HER2+ and HER2- groups, suggests a role for 64Cu-DOTA-trastuzumab PET/CT in optimizing treatments that include trastuzumab.The goal of this study was to characterize the relationship between tumor uptake of 64Cu-DOTA-trastuzumab as measured by PET/CT and standard, immunohistochemistry (IHC)-based, histopathologic classification of human epidermal growth factor receptor 2 (HER2) status in women with metastatic breast cancer (MBC). Methods: Women with biopsy-confirmed MBC and not given trastuzumab for 2 mo or more underwent complete staging, including 18F-FDG PET/CT. Patients were classified as HER2-positive (HER2+) or -negative (HER2-) based on fluorescence in situ hybridization (FISH)-supplemented immunohistochemistry of biopsied tumor tissue. Eighteen patients underwent 64Cu-DOTA-trastuzumab injection, preceded in 16 cases by trastuzumab infusion (45 mg). PET/CT was performed 21-25 (day 1) and 47-49 (day 2) h after 64Cu-DOTA-trastuzumab injection. Radiolabel uptake in prominent lesions was measured as SUVmax Average intrapatient SUVmax (pt) was compared between HER2+ and HER2- patients. Results: Eleven women were HER2+ (8 immunohistochemistry 3+; 3 immunohistochemistry 2+/FISH amplified), whereas 7 were HER2- (3 immunohistochemistry 2+/FISH nonamplified; 4 immunohistochemistry 1+). Median pt for day 1 and day 2 was 6.6 and 6.8 g/mL for HER 2+ and 3.7 and 4.3 g/mL for HER2- patients (P < 0.005 either day). The distributions of pt overlapped between the 2 groups, and interpatient variability was greater for HER2+ than HER2- disease (P < 0.005 and 0.001, respectively, on days 1 and 2). Conclusion: By 1 d after injection, uptake of 64Cu-DOTA-trastuzumab in MBC is strongly associated with patient HER2 status and is indicative of binding to HER2. The variability within and among HER2+ patients, as well as the overlap between the HER2+ and HER2- groups, suggests a role for 64Cu-DOTA-trastuzumab PET/CT in optimizing treatments that include trastuzumab.</description><identifier>ISSN: 1535-5667</identifier><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><identifier>DOI: 10.2967/jnumed.117.193888</identifier><identifier>PMID: 28637802</identifier><language>eng</language><publisher>Society of Nuclear Medicine</publisher><subject>Oncology</subject><ispartof>The Journal of nuclear medicine (1978), 2018-01, Vol.59 (1), p.38-43</ispartof><rights>2018 by the Society of Nuclear Medicine and Molecular Imaging.</rights><rights>2018 by the Society of Nuclear Medicine and Molecular Imaging. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids></links><search><creatorcontrib>Mortimer, Joanne E</creatorcontrib><creatorcontrib>Bading, James R</creatorcontrib><creatorcontrib>Park, Jinha M</creatorcontrib><creatorcontrib>Frankel, Paul H</creatorcontrib><creatorcontrib>Carroll, Mary I</creatorcontrib><creatorcontrib>Tran, Tri T</creatorcontrib><creatorcontrib>Poku, Erasmus K</creatorcontrib><creatorcontrib>Rockne, Russell C</creatorcontrib><creatorcontrib>Raubitschek, Andrew A</creatorcontrib><creatorcontrib>Shively, John E</creatorcontrib><creatorcontrib>Colcher, David M</creatorcontrib><title>Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer</title><title>The Journal of nuclear medicine (1978)</title><description>The goal of this study was to characterize the relationship between tumor uptake of 64Cu-DOTA-trastuzumab as measured by PET/CT and standard, immunohistochemistry (IHC)-based, histopathologic classification of human epidermal growth factor receptor 2 (HER2) status in women with metastatic breast cancer (MBC). Methods: Women with biopsy-confirmed MBC and not given trastuzumab for 2 mo or more underwent complete staging, including 18F-FDG PET/CT. Patients were classified as HER2-positive (HER2+) or -negative (HER2-) based on fluorescence in situ hybridization (FISH)-supplemented immunohistochemistry of biopsied tumor tissue. Eighteen patients underwent 64Cu-DOTA-trastuzumab injection, preceded in 16 cases by trastuzumab infusion (45 mg). PET/CT was performed 21-25 (day 1) and 47-49 (day 2) h after 64Cu-DOTA-trastuzumab injection. Radiolabel uptake in prominent lesions was measured as SUVmax Average intrapatient SUVmax (pt) was compared between HER2+ and HER2- patients. Results: Eleven women were HER2+ (8 immunohistochemistry 3+; 3 immunohistochemistry 2+/FISH amplified), whereas 7 were HER2- (3 immunohistochemistry 2+/FISH nonamplified; 4 immunohistochemistry 1+). Median pt for day 1 and day 2 was 6.6 and 6.8 g/mL for HER 2+ and 3.7 and 4.3 g/mL for HER2- patients (P < 0.005 either day). The distributions of pt overlapped between the 2 groups, and interpatient variability was greater for HER2+ than HER2- disease (P < 0.005 and 0.001, respectively, on days 1 and 2). Conclusion: By 1 d after injection, uptake of 64Cu-DOTA-trastuzumab in MBC is strongly associated with patient HER2 status and is indicative of binding to HER2. The variability within and among HER2+ patients, as well as the overlap between the HER2+ and HER2- groups, suggests a role for 64Cu-DOTA-trastuzumab PET/CT in optimizing treatments that include trastuzumab.The goal of this study was to characterize the relationship between tumor uptake of 64Cu-DOTA-trastuzumab as measured by PET/CT and standard, immunohistochemistry (IHC)-based, histopathologic classification of human epidermal growth factor receptor 2 (HER2) status in women with metastatic breast cancer (MBC). Methods: Women with biopsy-confirmed MBC and not given trastuzumab for 2 mo or more underwent complete staging, including 18F-FDG PET/CT. Patients were classified as HER2-positive (HER2+) or -negative (HER2-) based on fluorescence in situ hybridization (FISH)-supplemented immunohistochemistry of biopsied tumor tissue. Eighteen patients underwent 64Cu-DOTA-trastuzumab injection, preceded in 16 cases by trastuzumab infusion (45 mg). PET/CT was performed 21-25 (day 1) and 47-49 (day 2) h after 64Cu-DOTA-trastuzumab injection. Radiolabel uptake in prominent lesions was measured as SUVmax Average intrapatient SUVmax (pt) was compared between HER2+ and HER2- patients. Results: Eleven women were HER2+ (8 immunohistochemistry 3+; 3 immunohistochemistry 2+/FISH amplified), whereas 7 were HER2- (3 immunohistochemistry 2+/FISH nonamplified; 4 immunohistochemistry 1+). Median pt for day 1 and day 2 was 6.6 and 6.8 g/mL for HER 2+ and 3.7 and 4.3 g/mL for HER2- patients (P < 0.005 either day). The distributions of pt overlapped between the 2 groups, and interpatient variability was greater for HER2+ than HER2- disease (P < 0.005 and 0.001, respectively, on days 1 and 2). Conclusion: By 1 d after injection, uptake of 64Cu-DOTA-trastuzumab in MBC is strongly associated with patient HER2 status and is indicative of binding to HER2. The variability within and among HER2+ patients, as well as the overlap between the HER2+ and HER2- groups, suggests a role for 64Cu-DOTA-trastuzumab PET/CT in optimizing treatments that include trastuzumab.</description><subject>Oncology</subject><issn>1535-5667</issn><issn>0161-5505</issn><issn>1535-5667</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpVkEtPwzAQhC0EolD4Adx85JLitWM7viCV8JSKyiE9R67r0JS8iG0Q_Hos0QOcdrSz-jSzCF0AmVEl5NWuC63dzADkDBTLsuwAnQBnPOFCyMM_eoJOndsRQkQ8OkYTmgkmM0JP0LIIbT_i1eD1m8V9hUWah-R2WcyTYtTOh-_Q6jWuO_yifW077_Bn7bf42froxpXBN6ONEue6M3Y8Q0eVbpw9388pWt3fFfljslg-POXzRTJQED6pNpZKMKmqjAINgvMNs4aB5JUFC4pkIFUqYiujJQem5BqIrKQWFaEKLJui61_uENbxByYmG3VTDmPd6vGr7HVd_ne6elu-9h8ll5xwyiLgcg8Y-_dgnS_b2hnbNLqzfXAlKKCCKKJS9gNmc2tm</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Mortimer, Joanne E</creator><creator>Bading, James R</creator><creator>Park, Jinha M</creator><creator>Frankel, Paul H</creator><creator>Carroll, Mary I</creator><creator>Tran, Tri T</creator><creator>Poku, Erasmus K</creator><creator>Rockne, Russell C</creator><creator>Raubitschek, Andrew A</creator><creator>Shively, John E</creator><creator>Colcher, David M</creator><general>Society of Nuclear Medicine</general><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180101</creationdate><title>Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer</title><author>Mortimer, Joanne E ; Bading, James R ; Park, Jinha M ; Frankel, Paul H ; Carroll, Mary I ; Tran, Tri T ; Poku, Erasmus K ; Rockne, Russell C ; Raubitschek, Andrew A ; Shively, John E ; Colcher, David M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p216t-fde271c49fc91a1655d3ec3175fe1e190817946193ca751397b107f7a6f0291e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mortimer, Joanne E</creatorcontrib><creatorcontrib>Bading, James R</creatorcontrib><creatorcontrib>Park, Jinha M</creatorcontrib><creatorcontrib>Frankel, Paul H</creatorcontrib><creatorcontrib>Carroll, Mary I</creatorcontrib><creatorcontrib>Tran, Tri T</creatorcontrib><creatorcontrib>Poku, Erasmus K</creatorcontrib><creatorcontrib>Rockne, Russell C</creatorcontrib><creatorcontrib>Raubitschek, Andrew A</creatorcontrib><creatorcontrib>Shively, John E</creatorcontrib><creatorcontrib>Colcher, David M</creatorcontrib><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of nuclear medicine (1978)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mortimer, Joanne E</au><au>Bading, James R</au><au>Park, Jinha M</au><au>Frankel, Paul H</au><au>Carroll, Mary I</au><au>Tran, Tri T</au><au>Poku, Erasmus K</au><au>Rockne, Russell C</au><au>Raubitschek, Andrew A</au><au>Shively, John E</au><au>Colcher, David M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer</atitle><jtitle>The Journal of nuclear medicine (1978)</jtitle><date>2018-01-01</date><risdate>2018</risdate><volume>59</volume><issue>1</issue><spage>38</spage><epage>43</epage><pages>38-43</pages><issn>1535-5667</issn><issn>0161-5505</issn><eissn>1535-5667</eissn><abstract>The goal of this study was to characterize the relationship between tumor uptake of 64Cu-DOTA-trastuzumab as measured by PET/CT and standard, immunohistochemistry (IHC)-based, histopathologic classification of human epidermal growth factor receptor 2 (HER2) status in women with metastatic breast cancer (MBC). Methods: Women with biopsy-confirmed MBC and not given trastuzumab for 2 mo or more underwent complete staging, including 18F-FDG PET/CT. Patients were classified as HER2-positive (HER2+) or -negative (HER2-) based on fluorescence in situ hybridization (FISH)-supplemented immunohistochemistry of biopsied tumor tissue. Eighteen patients underwent 64Cu-DOTA-trastuzumab injection, preceded in 16 cases by trastuzumab infusion (45 mg). PET/CT was performed 21-25 (day 1) and 47-49 (day 2) h after 64Cu-DOTA-trastuzumab injection. Radiolabel uptake in prominent lesions was measured as SUVmax Average intrapatient SUVmax (pt) was compared between HER2+ and HER2- patients. Results: Eleven women were HER2+ (8 immunohistochemistry 3+; 3 immunohistochemistry 2+/FISH amplified), whereas 7 were HER2- (3 immunohistochemistry 2+/FISH nonamplified; 4 immunohistochemistry 1+). Median pt for day 1 and day 2 was 6.6 and 6.8 g/mL for HER 2+ and 3.7 and 4.3 g/mL for HER2- patients (P < 0.005 either day). The distributions of pt overlapped between the 2 groups, and interpatient variability was greater for HER2+ than HER2- disease (P < 0.005 and 0.001, respectively, on days 1 and 2). Conclusion: By 1 d after injection, uptake of 64Cu-DOTA-trastuzumab in MBC is strongly associated with patient HER2 status and is indicative of binding to HER2. The variability within and among HER2+ patients, as well as the overlap between the HER2+ and HER2- groups, suggests a role for 64Cu-DOTA-trastuzumab PET/CT in optimizing treatments that include trastuzumab.The goal of this study was to characterize the relationship between tumor uptake of 64Cu-DOTA-trastuzumab as measured by PET/CT and standard, immunohistochemistry (IHC)-based, histopathologic classification of human epidermal growth factor receptor 2 (HER2) status in women with metastatic breast cancer (MBC). Methods: Women with biopsy-confirmed MBC and not given trastuzumab for 2 mo or more underwent complete staging, including 18F-FDG PET/CT. Patients were classified as HER2-positive (HER2+) or -negative (HER2-) based on fluorescence in situ hybridization (FISH)-supplemented immunohistochemistry of biopsied tumor tissue. Eighteen patients underwent 64Cu-DOTA-trastuzumab injection, preceded in 16 cases by trastuzumab infusion (45 mg). PET/CT was performed 21-25 (day 1) and 47-49 (day 2) h after 64Cu-DOTA-trastuzumab injection. Radiolabel uptake in prominent lesions was measured as SUVmax Average intrapatient SUVmax (pt) was compared between HER2+ and HER2- patients. Results: Eleven women were HER2+ (8 immunohistochemistry 3+; 3 immunohistochemistry 2+/FISH amplified), whereas 7 were HER2- (3 immunohistochemistry 2+/FISH nonamplified; 4 immunohistochemistry 1+). Median pt for day 1 and day 2 was 6.6 and 6.8 g/mL for HER 2+ and 3.7 and 4.3 g/mL for HER2- patients (P < 0.005 either day). The distributions of pt overlapped between the 2 groups, and interpatient variability was greater for HER2+ than HER2- disease (P < 0.005 and 0.001, respectively, on days 1 and 2). Conclusion: By 1 d after injection, uptake of 64Cu-DOTA-trastuzumab in MBC is strongly associated with patient HER2 status and is indicative of binding to HER2. The variability within and among HER2+ patients, as well as the overlap between the HER2+ and HER2- groups, suggests a role for 64Cu-DOTA-trastuzumab PET/CT in optimizing treatments that include trastuzumab.</abstract><pub>Society of Nuclear Medicine</pub><pmid>28637802</pmid><doi>10.2967/jnumed.117.193888</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1535-5667 |
| ispartof | The Journal of nuclear medicine (1978), 2018-01, Vol.59 (1), p.38-43 |
| issn | 1535-5667 0161-5505 1535-5667 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5750523 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Oncology |
| title | Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T13%3A34%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumor%20Uptake%20of%2064Cu-DOTA-Trastuzumab%20in%20Patients%20with%20Metastatic%20Breast%20Cancer&rft.jtitle=The%20Journal%20of%20nuclear%20medicine%20(1978)&rft.au=Mortimer,%20Joanne%20E&rft.date=2018-01-01&rft.volume=59&rft.issue=1&rft.spage=38&rft.epage=43&rft.pages=38-43&rft.issn=1535-5667&rft.eissn=1535-5667&rft_id=info:doi/10.2967/jnumed.117.193888&rft_dat=%3Cproquest_pubme%3E1912609094%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1912609094&rft_id=info:pmid/28637802&rfr_iscdi=true |